Prasugrel



Indications and Reactions:

Role Indications Reactions
Primary
Coronary Arterial Stent Insertion 37.2%
Stent Placement 14.0%
Coronary Artery Disease 11.6%
Antiplatelet Therapy 9.3%
Dermatitis Allergic 4.7%
Postoperative Care 4.7%
Angiogram 2.3%
Catheterisation Cardiac 2.3%
Cerebrovascular Accident Prophylaxis 2.3%
Cerebrovascular Disorder 2.3%
Coronary Stent Insertion 2.3%
Coronary Stent Placement 2.3%
Drug-eluting Coronary Stent Placement 2.3%
Surgery 2.3%
Rash 14.8%
Angina Unstable 7.4%
Haemorrhage 7.4%
Thrombosis In Device 7.4%
Treatment Failure 7.4%
Cerebral Haemorrhage 3.7%
Chromaturia 3.7%
Dizziness 3.7%
Drug Ineffective 3.7%
Fall 3.7%
Gastric Haemorrhage 3.7%
Gastrointestinal Haemorrhage 3.7%
Haemoglobin Decreased 3.7%
Haemorrhage Intracranial 3.7%
Haemorrhagic Stroke 3.7%
Hypertension 3.7%
Pain 3.7%
Platelet Count Decreased 3.7%
Road Traffic Accident 3.7%
Thrombotic Thrombocytopenic Purpura 3.7%
Secondary
Product Used For Unknown Indication 16.6%
Acute Coronary Syndrome 14.3%
Percutaneous Coronary Intervention 9.2%
Acute Myocardial Infarction 7.8%
Drug Use For Unknown Indication 6.5%
Antiplatelet Therapy 6.0%
Coronary Artery Disease 5.1%
Myocardial Infarction 4.6%
Dyslipidaemia 3.7%
Ill-defined Disorder 3.7%
Hypertension 3.2%
Platelet Count Increased 2.8%
Prevention 2.8%
Stent Placement 2.8%
Myocardial Ischaemia 2.3%
Back Pain 1.8%
Coagulopathy 1.8%
Thrombosis Prophylaxis 1.8%
Vitamin Supplementation 1.8%
Cardiovascular Event Prophylaxis 1.4%
Thrombocytopenia 11.4%
Haemorrhage Intracranial 9.1%
Coronary Angioplasty 6.8%
Retroperitoneal Haematoma 6.8%
Cardiogenic Shock 4.5%
Coma Scale Abnormal 4.5%
Coronary Artery Thrombosis 4.5%
Cytolytic Hepatitis 4.5%
Duodenal Ulcer Haemorrhage 4.5%
Epistaxis 4.5%
Haematocrit Decreased 4.5%
Melaena 4.5%
Pneumonia 4.5%
Puncture Site Haemorrhage 4.5%
Rhabdomyolysis 4.5%
Subarachnoid Haemorrhage 4.5%
Systemic Inflammatory Response Syndrome 4.5%
Adverse Drug Reaction 2.3%
Agitation 2.3%
Altered State Of Consciousness 2.3%
Concomitant
Product Used For Unknown Indication 24.7%
Myocardial Infarction 8.7%
Drug Use For Unknown Indication 8.1%
Acute Myocardial Infarction 7.4%
Hypertension 6.1%
Percutaneous Coronary Intervention 5.7%
Premedication 5.2%
Anticoagulant Therapy 3.7%
Hypersensitivity 3.5%
Antiplatelet Therapy 3.1%
Prophylaxis 3.1%
Acute Coronary Syndrome 2.8%
Cardiac Failure 2.6%
Myocardial Ischaemia 2.6%
Pain 2.4%
Stent Placement 2.4%
Antibiotic Prophylaxis 2.2%
Blood Cholesterol Increased 2.2%
Depression 2.0%
Angina Pectoris 1.5%
Myocardial Infarction 11.9%
Rhabdomyolysis 10.4%
Tachycardia 10.4%
Thrombosis In Device 9.0%
Incorrect Route Of Drug Administration 7.5%
Hypotension 4.5%
Impaired Driving Ability 4.5%
Off Label Use 4.5%
Vascular Operation 4.5%
Acute Coronary Syndrome 3.0%
Acute Myocardial Infarction 3.0%
Bradycardia 3.0%
Chronic Obstructive Pulmonary Disease 3.0%
Coronary Artery Restenosis 3.0%
Flushing 3.0%
Hyperbilirubinaemia 3.0%
Malaise 3.0%
Normochromic Normocytic Anaemia 3.0%
Pain In Extremity 3.0%
Peripheral Arterial Occlusive Disease 3.0%
Interacting
Antiplatelet Therapy 38.0%
Product Used For Unknown Indication 13.0%
Acute Myocardial Infarction 8.7%
Coronary Artery Disease 6.5%
Atrial Fibrillation 4.3%
Carotid Artery Aneurysm 4.3%
Catheterisation Cardiac 3.3%
Cerebrovascular Accident Prophylaxis 3.3%
Ischaemic Heart Disease Prophylaxis 3.3%
Blood Pressure Abnormal 2.2%
Intracranial Aneurysm 2.2%
Stent Placement 2.2%
Agitation 1.1%
Arrhythmia 1.1%
Blood Cholesterol Increased 1.1%
Coronary Angioplasty 1.1%
Diabetes Mellitus 1.1%
Hypercholesterolaemia 1.1%
Hypotension 1.1%
Hypothyroidism 1.1%
Vessel Perforation 22.2%
Upper Gastrointestinal Haemorrhage 16.7%
Labelled Drug-drug Interaction Medication Error 11.1%
Anaemia 5.6%
Epistaxis 5.6%
Gastrointestinal Haemorrhage 5.6%
Haematochezia 5.6%
Haemoglobin Decreased 5.6%
Haemorrhage 5.6%
Incision Site Haemorrhage 5.6%
Myocardial Infarction 5.6%
Myocardial Ischaemia 5.6%